CN107074817B - 用于成像亨廷顿蛋白的探针 - Google Patents

用于成像亨廷顿蛋白的探针 Download PDF

Info

Publication number
CN107074817B
CN107074817B CN201580058254.1A CN201580058254A CN107074817B CN 107074817 B CN107074817 B CN 107074817B CN 201580058254 A CN201580058254 A CN 201580058254A CN 107074817 B CN107074817 B CN 107074817B
Authority
CN
China
Prior art keywords
alkyl
group
imaging
pyridine
pet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580058254.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107074817A (zh
Inventor
C·多敏古兹
J·维恰克
J·巴德
C·J·布朗
T·M·克吕尔
D·克拉克-弗鲁
S·海耶斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHDI Foundation
Original Assignee
CHDI Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHDI Foundation filed Critical CHDI Foundation
Priority to CN202311625463.2A priority Critical patent/CN118005611A/zh
Publication of CN107074817A publication Critical patent/CN107074817A/zh
Application granted granted Critical
Publication of CN107074817B publication Critical patent/CN107074817B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CN201580058254.1A 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针 Active CN107074817B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311625463.2A CN118005611A (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043644P 2014-08-29 2014-08-29
US62/043,644 2014-08-29
PCT/US2015/047396 WO2016033436A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311625463.2A Division CN118005611A (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针

Publications (2)

Publication Number Publication Date
CN107074817A CN107074817A (zh) 2017-08-18
CN107074817B true CN107074817B (zh) 2023-12-15

Family

ID=55400644

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580058254.1A Active CN107074817B (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针
CN202311625463.2A Pending CN118005611A (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311625463.2A Pending CN118005611A (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针

Country Status (20)

Country Link
US (2) US11071793B2 (cg-RX-API-DMAC10.html)
EP (1) EP3186241B1 (cg-RX-API-DMAC10.html)
JP (3) JP2017527559A (cg-RX-API-DMAC10.html)
KR (1) KR102410760B1 (cg-RX-API-DMAC10.html)
CN (2) CN107074817B (cg-RX-API-DMAC10.html)
AU (1) AU2015308765B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017004136B1 (cg-RX-API-DMAC10.html)
CA (1) CA2959531C (cg-RX-API-DMAC10.html)
DK (1) DK3186241T3 (cg-RX-API-DMAC10.html)
EA (1) EA037275B1 (cg-RX-API-DMAC10.html)
ES (1) ES2841746T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20202032T1 (cg-RX-API-DMAC10.html)
HU (1) HUE052892T2 (cg-RX-API-DMAC10.html)
IL (1) IL250805B (cg-RX-API-DMAC10.html)
MX (2) MX383202B (cg-RX-API-DMAC10.html)
PL (1) PL3186241T3 (cg-RX-API-DMAC10.html)
PT (1) PT3186241T (cg-RX-API-DMAC10.html)
SG (1) SG11201701578YA (cg-RX-API-DMAC10.html)
SI (1) SI3186241T1 (cg-RX-API-DMAC10.html)
WO (1) WO2016033436A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
SG11201701578YA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
PL3197277T3 (pl) 2014-08-29 2022-04-04 Chdi Foundation, Inc. Sondy do obrazowania molekularnego białka huntingtyny
CA2995847C (en) 2015-08-28 2024-05-28 Chdi Foundation, Inc. Probes for imaging huntingtin protein
WO2018049328A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
KR102537985B1 (ko) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
US11992535B2 (en) * 2019-12-18 2024-05-28 Chdi Foundation, Inc. Compounds and probes for imaging huntingtin protein
IL298941A (en) 2020-06-11 2023-02-01 Chdi Foundation Inc Heterocyclic compounds and imaging agents for the imaging of huntingtin protein
MX2023011888A (es) * 2021-04-08 2023-12-06 Chdi Foundation Inc Compuestos de isoindolinona y agentes de formación de imágenes para la obtencion de imágenes de la proteína huntingtina.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076969A1 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
WO2009042907A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
CN101500995A (zh) * 2006-03-17 2009-08-05 美国政府卫生与公共服务部 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物
WO2010104324A2 (ko) * 2009-03-10 2010-09-16 한국과학기술연구원 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를 가지는 할로겐화 이소인돌론 화합물, 및 이의 제조 방법 및 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726197A (en) * 1992-11-02 1998-03-10 Syntex (U.S.A.) Inc. Isoindolinyl derivatives
KR101011657B1 (ko) * 2002-03-01 2011-01-28 다케다 야쿠힌 고교 가부시키가이샤 항우울제
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP5632612B2 (ja) * 2007-12-05 2014-11-26 あすか製薬株式会社 ラクタム化合物又はその塩及びｐｐａｒ活性化剤
ES2645984T3 (es) * 2012-04-25 2017-12-11 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de TTX-S
CN104903312B (zh) * 2013-10-07 2019-01-29 卡德门企业有限公司 Rho激酶抑制剂
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
PL3197277T3 (pl) 2014-08-29 2022-04-04 Chdi Foundation, Inc. Sondy do obrazowania molekularnego białka huntingtyny
SG11201701578YA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
CA2995847C (en) 2015-08-28 2024-05-28 Chdi Foundation, Inc. Probes for imaging huntingtin protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076969A1 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
CN101500995A (zh) * 2006-03-17 2009-08-05 美国政府卫生与公共服务部 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物
WO2009042907A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2010104324A2 (ko) * 2009-03-10 2010-09-16 한국과학기술연구원 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를 가지는 할로겐화 이소인돌론 화합물, 및 이의 제조 방법 및 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
郭宗儒.基团变化对活性的影响.《药物化学总论》.2003,第128-130页. *

Also Published As

Publication number Publication date
MX383202B (es) 2025-03-13
JP2021088584A (ja) 2021-06-10
IL250805A0 (en) 2017-04-30
JP6843282B2 (ja) 2021-03-17
PT3186241T (pt) 2021-01-08
AU2015308765A1 (en) 2017-03-23
US20170281804A1 (en) 2017-10-05
CN107074817A (zh) 2017-08-18
EA037275B1 (ru) 2021-03-03
US11071793B2 (en) 2021-07-27
CA2959531C (en) 2023-01-10
JP2017527559A (ja) 2017-09-21
US20210379211A1 (en) 2021-12-09
AU2015308765B2 (en) 2020-06-04
MX2017002704A (es) 2017-10-23
EA201790432A1 (ru) 2017-09-29
EP3186241A1 (en) 2017-07-05
BR112017004136A2 (pt) 2017-12-12
HRP20202032T1 (hr) 2021-02-19
JP2020079272A (ja) 2020-05-28
CA2959531A1 (en) 2016-03-03
ES2841746T3 (es) 2021-07-09
IL250805B (en) 2020-08-31
EP3186241A4 (en) 2018-04-18
CN118005611A (zh) 2024-05-10
PL3186241T3 (pl) 2021-05-17
MX2021005891A (es) 2021-06-23
WO2016033436A1 (en) 2016-03-03
HUE052892T2 (hu) 2021-05-28
JP7042940B2 (ja) 2022-03-28
KR102410760B1 (ko) 2022-06-20
EP3186241B1 (en) 2020-10-07
SI3186241T1 (sl) 2021-03-31
BR112017004136B1 (pt) 2022-05-03
KR20170047348A (ko) 2017-05-04
US12036291B2 (en) 2024-07-16
SG11201701578YA (en) 2017-03-30
DK3186241T3 (da) 2021-01-11

Similar Documents

Publication Publication Date Title
US12036291B2 (en) Probes for imaging huntingtin protein
US11851446B2 (en) Probes for imaging Huntingtin protein
CN108135172B (zh) 用于成像亨廷顿蛋白的探针
US10907197B2 (en) Probes for imaging huntingtin protein
KR20240024045A (ko) 헌팅틴 단백질 영상화를 위한 아이소인돌리논 화합물 및 영상화제
HK40110855A (en) Probes for imaging huntingtin protein
HK1240582A1 (en) Probes for imaging huntington protein
HK1240582B (en) Probes for imaging huntington protein
HK1241224B (en) Probes for imaging huntingtin protein
HK1241223A1 (en) Probes for imaging huntingtin protein
HK1241223B (en) Probes for imaging huntingtin protein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20351103

TG01 Patent term adjustment